Breve descripción
El estudio está diseñado como un estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y seguridad de iptacopan (LNP023) en la glomerulopatía del complemento 3.
Médico del ensayo / Coordinador del estudio
Sherry Wilson
Estimated Enrollment
2
Estimated End Date
diciembre 2025
Trial is for people with
Adolescent Patient with C3 Glomerulopathy (C3G)
Study Goal
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to placebo and standard of care in patients ...
What is involved for the patient?
Patients will be asked to attend a screening visit to assess eligibly. Medical history will be collected. The study team will collect ...
About the drug or intervention
LNP023/iptacopan is an investigational drug that we are studying as a potential targeted treatment for people with C3G and other ...